

Limited Submission Funding Opportunities – updated 7/12/24

Please be aware that any grant that brings in less than 20% in indirect costs (IDC) will need to be supplemented up to the 20% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 20% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)

The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Institutional Research Training Grants for the Clinical and Translational Science Awards (CTSA) Program (T32) to eligible institutions to enhance postdoctoral research training of individuals with doctoral degrees (these include, but are not limited to, the following: D.M.D., DC, DO, DVM., OD, DPM, ScD, EngD, DrPH, DNSc, DPT, PharmD, ND [Doctor of Naturopathy], DSW, PsyD, as well as a doctoral degree in nursing research) and help ensure a heterogeneous pool of clinical and translational scientists trainees are equipped with the knowledge,

Limited Submission Funding Opportunities – updated 7/12/24

skills and abilities to advance diagnostics, therapeutics, clinical interventions, and behavioral modifications that improve health.

NCATS will not accept applications proposing combined predoctoral and postdoctoral training under this FOA. Applications proposing predoctoral research training should apply to the Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program ([PAR-21-337](#)).

The proposed institutional research training program may complement other ongoing research training and career development programs at the applicant institution but must be clearly distinct from related programs currently receiving Federal support.

This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial on which the PI is a mentor or co-mentor.

MGH LOI Deadline: 7/17/24

NIH Application Deadline: 9/13/24

[Learn more](#)

2. Susan G. Komen Career Catalyst Research Grants – NEW!

PURPOSE OF AWARD: For more than a decade, Susan G. Komen Career Catalyst Research (CCR) Grants have fostered promising breast cancer researchers who are in the early stages of their faculty careers by providing support for up to three years of “protected time” for research career development under the guidance of a Mentor Committee. We seek to support those who will emerge as the next key leaders in the fight against breast cancer.

GRANT TERMS: Applicants/Primary Investigators (PIs) may request funding of up to \$150,000 per year (combined direct and indirect costs) for up to three years (\$450,000).

WHO MAY APPLY?

Applicants must be Early Career Investigators that currently hold a faculty appointment or have a formal offer letter from the Institution that confirms position and start date by the Application due date (**October 9, 2024**) and have not been held any faculty appointment, including non-tenure and tenure track appointments combined, for more than a total of **6 years** by the Application due date (**October 9, 2024**). All positions that are considered as “Faculty” positions by the Applicant/PIs institution (or prior institution) count towards the 6-year limit. This may include positions such as Instructor, Research Fellow, or other non-tenure track faculty positions as appropriate.

MGH LOI Deadline: 7/19/24

Sponsor LOI Deadline: 8/07/24

Sponsor invited Application Deadline: 10/09/24

[Learn more](#)

Limited Submission Funding Opportunities – updated 7/12/24

3. Susan G. Komen Career Transition Awards – NEW!

PURPOSE OF AWARD: This Susan G. Komen grant mechanism aims to help outstanding senior postdoctoral fellows and clinical fellows, working under the guidance of a mentor, launch their competitive, independent breast cancer research careers. Career Transition Awards provide up to five years of funding in two phases: Phase 1 supports the final years of mentored, postdoctoral training; and Phase 2 supports the independent research of the early career, tenure-track investigators. By supporting the most promising scientists and clinician-scientists as they embark on independent careers dedicated to breast cancer research, Komen seeks to ensure that a diverse group of highly trained scientists, who reflect the communities we serve, will emerge as the next generation of leaders in breast cancer research.

GRANT TERMS: Applicant/PI may request up to 5 years of funding totaling up to \$650,000.00 over the two phases of the Award. Up to \$100,000.00 per year (direct costs only) for up to two years may be requested for the first phase of the Career Transition Award to support the postdoctoral work. For the second phase of the Career Transition Award, the Applicant/PI may request up to \$150,000.00 per year (direct and indirect costs) for up to three years to support independent research.

MGH LOI Deadline: 7/19/24

Sponsor LOI Deadline: 8/07/24

Sponsor invited Application Deadline: 10/09/24

[Learn more](#)

4. Cummings \$30 Million Grant Programs – NEW!

The Cummings \$30 Million Grant Program funds a wide variety of local causes, especially those related to human services, education, healthcare, and social justice. While not in any way minimizing the value or importance of organizations focused on the arts (including dance, music, and theater), culture, environment, athletics, or the preservation of land or historic buildings, these areas are not among this program's priorities. To ensure that funds benefit a wide variety of causes, the Foundation limits the number of grants awarded each year to independent organizations affiliated with the same national organization (e.g., Boys & Girls Clubs, YMCA).

Award Amount: All requests should be written with a three-year grant in mind. Applicants may request annual installments of \$10,000 to \$100,000, and round numbers are preferred (e.g., \$40,000 instead of \$42,599). Also, installments will remain constant throughout the term of a grant.

MGH LOI Deadline: 8/01/24

Sponsor LOI Deadline: 9/06/24

Sponsor invited Application Deadline: 12/18/24

[Learn more](#)

5. Medical Scientist Training Program (MSTP) (T32)

The goal of the Medical Scientist Training Program (MSTP) is to develop a diverse pool of well-trained clinician-scientist leaders available to address the nation's biomedical research needs. Specifically, this funding announcement provides support to eligible, domestic organizations to develop and implement effective, evidence-informed approaches to dual-degree training and mentoring that will keep pace with

Limited Submission Funding Opportunities – updated 7/12/24

the rapid evolution of the biomedical research enterprise and lead to the completion of both a clinical degree (for example, M.D., D.O., D.V.M., D.D.S., Pharm.D., etc.) and a research doctorate degree (Ph.D.).

With the dual qualifications of a rigorous scientist and clinician, graduates will be equipped with the skills to develop research programs that accelerate the translation of research advances to the understanding, detection, treatment, and prevention of human disease, and to lead the advancement of biomedical research. Areas of particular importance to NIGMS are optimizing training efficiency, fostering the persistence of alumni in research careers, and enhancing the diversity of the clinician-scientist workforce. NIGMS expects that the proposed research training program will incorporate didactic, research, mentoring and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the nation.

This Notice of Funding Opportunity (NOFO) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

MGH LOI Deadline: 8/14/24

NIH Application Deadline: 9/25/24

[Learn more](#)